{"references":[{"authors":["Yusuke Higuchi","Tatsuya Suzuki","Takao Arimori","Nariko Ikemura","Emiko Mihara","Yuhei Kirita","Eriko Ohgitani","Osam Mazda","Daisuke Motooka","Shota Nakamura","Yusuke Sakai","Yumi Itoh","Fuminori Sugihara","Yoshiharu Matsuura","Satoaki Matoba","Toru Okamoto","Junichi Takagi","Atsushi Hoshino"],"doi":"10.1038/s41467-021-24013-y","title":"Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2"},{"authors":["P Zhou"],"raw":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270-273 (2020).","title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","venue":"Nature","year":2020},{"authors":["F Wu"],"raw":"Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265-269 (2020).","title":"A new coronavirus associated with human respiratory disease in China","venue":"Nature","year":2020},{"authors":["M Letko","A Marzi","V Munster"],"raw":"Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 5, 562-569 (2020).","title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","venue":"Nat. Microbiol","year":2020},{"authors":["D Wrapp"],"raw":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260-1263 (2020).","title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","venue":"Science","year":2020},{"authors":["R Shi"],"raw":"Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120-124 (2020).","title":"A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","venue":"Nature","year":2020},{"authors":["B Ju"],"raw":"Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584, 115-119 (2020).","title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","venue":"Nature","year":2020},{"authors":["Y Cao"],"raw":"Cao, Y. et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients B cells. Cell 182, 73-84 e16 (2020).","title":"Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients B cells","venue":"Cell","year":2020},{"authors":["E C Smith","N R Sexton","M R Denison"],"raw":"Smith, E. C., Sexton, N. R. & Denison, M. R. Thinking outside the triangle: replication fidelity of the largest RNA viruses. Annu Rev. Virol. 1, 111-132 (2014).","title":"Thinking outside the triangle: replication fidelity of the largest RNA viruses","venue":"Annu Rev. Virol","year":2014},{"authors":["L Van Dorp"],"raw":"van Dorp, L. et al. No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2. Nat. Commun. 11, 5986 (2020).","title":"No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2","venue":"Nat. Commun","year":2020},{"authors":["T N Starr"],"raw":"Starr, T. N. et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science. 371, 850-854 (2020).","title":"Prospective mapping of viral mutations that escape antibodies used to treat COVID-19","venue":"Science","year":2020},{"authors":["Y Weisblum"],"raw":"Weisblum, Y. et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife. 9, e61312 (2020).","title":"Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants","year":2020},{"authors":["E Andreano"],"doi":"10.1101/2020.12.28.424451v1","raw":"Andreano, E., et al. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. Preprint at https://www.biorxiv.org/content/ 10.1101/2020.12.28.424451v1 (2020).","title":"SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma","url":"https://www.biorxiv.org/content/10.1101/2020.12.28.424451v1","year":2020},{"authors":["S A Kemp"],"raw":"Kemp, S. A. et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 592, 277-282 (2021).","title":"SARS-CoV-2 evolution during treatment of chronic infection","venue":"Nature","year":2021},{"authors":["V Monteil"],"raw":"Monteil, V. et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 181, 905-913 e907 (2020).","title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","venue":"Cell","year":2020},{"authors":["A Zoufaly"],"raw":"Zoufaly, A. et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir. Med 8, 1154-1158 (2020).","title":"Human recombinant soluble ACE2 in severe COVID-19","venue":"Lancet Respir. Med","year":2020},{"authors":["J Shang"],"raw":"Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221-224 (2020).","title":"Structural basis of receptor recognition by SARS-CoV-2","venue":"Nature","year":2020},{"authors":["K K Chan"],"raw":"Chan, K. K. et al. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science. 369, 1261-1265 (2020).","title":"Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2","venue":"Science","year":2020},{"authors":["A Glasgow"],"raw":"Glasgow, A. et al. Engineered ACE2 receptor traps potently neutralize SARS- CoV-2. Proc. Natl Acad. Sci. USA 117, 28046-28055 (2020).","title":"Engineered ACE2 receptor traps potently neutralize SARS-CoV-2","venue":"Proc. Natl Acad. Sci. USA","year":2020},{"authors":["D Gonzalez-Perez","E Garcia-Ruiz","M Alcalde"],"raw":"Gonzalez-Perez, D., Garcia-Ruiz, E. & Alcalde, M. Saccharomyces cerevisiae in directed evolution: an efficient tool to improve enzymes. Bioeng. Bugs 3, 172-177 (2012).","title":"Saccharomyces cerevisiae in directed evolution: an efficient tool to improve enzymes","venue":"Bioeng. Bugs","year":2012},{"authors":["K Swiech","M C De Freitas","D T Covas","V Picanco-Castro"],"raw":"Swiech, K., de Freitas, M. C., Covas, D. T. & Picanco-Castro, V. Recombinant glycoprotein production in human cell lines. Methods Mol. Biol. 1258, 223-240 (2015).","title":"Recombinant glycoprotein production in human cell lines","venue":"Methods Mol. Biol","year":2015},{"authors":["D J Benton"],"raw":"Benton, D. J. et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature 588, 327-330 (2020).","title":"Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion","venue":"Nature","year":2020},{"authors":["L Guo"],"raw":"Guo, L. et al. Engineered trimeric ACE2 binds viral spike protein and locks it in \"Three-up\" conformation to potently inhibit SARS-CoV-2 infection. Cell Res. 31, 98-100 (2021).","title":"Engineered trimeric ACE2 binds viral spike protein and locks it in \"Three-up\" conformation to potently inhibit SARS-CoV-2 infection","venue":"Cell Res","year":2021},{"authors":["J Wysocki"],"raw":"Wysocki, J. et al. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II- dependent hypertension. Hypertension 55, 90-98 (2010).","title":"Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin IIdependent hypertension","venue":"Hypertension","year":2010},{"authors":["M Haschke"],"raw":"Haschke, M. et al. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin. Pharmacokinet. 52, 783-792 (2013).","title":"Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects","venue":"Clin. Pharmacokinet","year":2013},{"authors":["Q Wang"],"raw":"Wang, Q. et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell 181, 894-904 e899 (2020).","title":"Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2","venue":"Cell","year":2020},{"authors":["J Lan"],"raw":"Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215-220 (2020).","title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","venue":"Nature","year":2020},{"authors":["R Yan"],"raw":"Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444-1448 (2020).","title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","venue":"Science","year":2020},{"authors":["P Towler"],"raw":"Towler, P. et al. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J. Biol. Chem. 279, 17996-18007 (2004).","title":"ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis","venue":"J. Biol. Chem","year":2004},{"authors":["M J Huentelman"],"raw":"Huentelman, M. J. et al. Structure-based discovery of a novel angiotensin- converting enzyme 2 inhibitor. Hypertension 44, 903-906 (2004).","title":"Structure-based discovery of a novel angiotensinconverting enzyme 2 inhibitor","venue":"Hypertension","year":2004},{"authors":["A Baum"],"raw":"Baum, A. et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 369, 1014-1018 (2020).","title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","venue":"Science","year":2020},{"authors":["Y Wu"],"raw":"Wu, Y. et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 368, 1274-1278 (2020).","title":"A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2","venue":"Science","year":2020},{"authors":["R E Chen"],"raw":"Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27, 717-726 (2021).","title":"Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies","venue":"Nat. Med","year":2021},{"authors":["D Zhou"],"raw":"Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 184, 2348-2361 e6 (2021).","title":"Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera","venue":"Cell","year":2021},{"authors":["M Imai"],"raw":"Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl Acad. Sci. USA 117, 16587-16595 (2020).","title":"Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development","venue":"Proc. Natl Acad. Sci. USA","year":2020},{"authors":["F R Carlson","D Bosukonda","P C Keck","W D Carlson"],"raw":"Carlson, F. R. Jr., Bosukonda, D., Keck, P. C. & Carlson, W. D. Multiorgan damage in patients with COVID-19: is the TGF-beta/BMP pathway the missing link? JACC Basic Transl. Sci. 5, 1145-1148 (2020).","title":"Multiorgan damage in patients with COVID-19: is the TGF-beta/BMP pathway the missing link?","venue":"JACC Basic Transl. Sci","year":2020},{"authors":["L Lu","H Zhang","D J Dauphars","Y W He"],"raw":"Lu, L., Zhang, H., Dauphars, D. J. & He, Y. W. A potential role of interleukin 10 in COVID-19 pathogenesis. Trends Immunol. 42, 3-5 (2021).","title":"A potential role of interleukin 10 in COVID-19 pathogenesis","venue":"Trends Immunol","year":2021},{"authors":["Y Imai"],"raw":"Imai, Y. et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436, 112-116 (2005).","title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","venue":"Nature","year":2005},{"authors":["M S Kariolis"],"raw":"Kariolis, M. S. et al. An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis. Nat. Chem. Biol. 10, 977-983 (2014).","title":"An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis","venue":"Nat. Chem. Biol","year":2014},{"authors":["J W Kim"],"raw":"Kim, J. W. et al. Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinoma. Nat. Med. 25, 1783-1795 (2019).","title":"Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinoma","venue":"Nat. Med","year":2019},{"authors":["N Iwanaga"],"doi":"10.1101/2020.06.15.152157v1","raw":"Iwanaga, N., et al. Novel ACE2-IgG1 fusions with improved activity against SARS-CoV2. Preprint at https://www.biorxiv.org/content/10.1101/ 2020.06.15.152157v1 (2020).","title":"Novel ACE2-IgG1 fusions with improved activity against SARS-CoV2","url":"https://www.biorxiv.org/content/10.1101/2020.06.15","year":2020},{"authors":["S Bournazos","D Corti","H W Virgin","J V Ravetch"],"raw":"Bournazos, S., Corti, D., Virgin, H. W. & Ravetch, J. V. Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. Nature 588, 485-490 (2020).","title":"Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection","venue":"Nature","year":2020},{"authors":["E S Winkler"],"raw":"Winkler, E. S. et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell. 184, 1804-1820 e16 (2021).","title":"Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection","venue":"Cell","year":2021},{"authors":["M G Tovey","C Lallemand"],"raw":"Tovey, M. G. & Lallemand, C. Immunogenicity and other problems associated with the use of biopharmaceuticals. Ther. Adv. Drug Saf. 2, 113-128 (2011).","title":"Immunogenicity and other problems associated with the use of biopharmaceuticals","venue":"Ther. Adv. Drug Saf","year":2011},{"authors":["L I Salazar-Fontana"],"raw":"Salazar-Fontana, L. I. et al. Approaches to mitigate the unwanted immunogenicity of therapeutic proteins during drug development. AAPS J. 19, 377-385 (2017).","title":"Approaches to mitigate the unwanted immunogenicity of therapeutic proteins during drug development","venue":"AAPS J","year":2017},{"authors":["S Barash","W Wang","Y Shi"],"raw":"Barash, S., Wang, W. & Shi, Y. Human secretory signal peptide description by hidden Markov model and generation of a strong artificial signal peptide for secreted protein expression. Biochem. Biophys. Res. Commun. 294, 835-842 (2002).","title":"Human secretory signal peptide description by hidden Markov model and generation of a strong artificial signal peptide for secreted protein expression","venue":"Biochem. Biophys. Res. Commun","year":2002},{"authors":["J Hansen"],"raw":"Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369, 1010-1014 (2020).","title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","venue":"Science","year":2020},{"authors":["A Sonn-Segev"],"raw":"Sonn-Segev, A. et al. Quantifying the heterogeneity of macromolecular machines by mass photometry. Nat. Commun. 11, 1772 (2020).","title":"Quantifying the heterogeneity of macromolecular machines by mass photometry","venue":"Nat. Commun","year":2020},{"authors":["W Kabsch","Xds"],"raw":"Kabsch, W. XDS. Acta Crystallogr. D. Biol. Crystallogr. 66, 125-132 (2010).","title":"Acta Crystallogr. D. Biol. Crystallogr","year":2010},{"authors":["A J Mccoy"],"raw":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).","title":"Phaser crystallographic software","venue":"J. Appl. Crystallogr","year":2007},{"authors":["M D Winn"],"raw":"Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D. Biol. Crystallogr. 67, 235-242 (2011).","title":"Overview of the CCP4 suite and current developments","venue":"Acta Crystallogr. D. Biol. Crystallogr","year":2011},{"authors":["P Emsley","B Lohkamp","W G Scott","K Cowtan"],"raw":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D. Biol. Crystallogr. 66, 486-501 (2010).","title":"Features and development of Coot","venue":"Acta Crystallogr. D. Biol. Crystallogr","year":2010},{"authors":["P D Adams"],"raw":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D. Biol. Crystallogr. 66, 213-221 (2010).","title":"PHENIX: a comprehensive Python-based system for macromolecular structure solution","venue":"Acta Crystallogr. D. Biol. Crystallogr","year":2010},{"authors":["V B Chen"],"raw":"Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D. Biol. Crystallogr. 66, 12-21 (2010).","title":"MolProbity: all-atom structure validation for macromolecular crystallography","venue":"Acta Crystallogr. D. Biol. Crystallogr","year":2010},{"authors":["F Li","W Li","M Farzan","S C Harrison"],"raw":"Li, F., Li, W., Farzan, M. & Harrison, S. C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309, 1864-1868 (2005).","title":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor","venue":"Science","year":2005},{"authors":["K H D Crawford"],"raw":"Crawford, K. H. D. et al. Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses. 12, 513 (2020).","title":"Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays","venue":"Viruses","year":2020},{"authors":["T Giroglou"],"raw":"Giroglou, T. et al. Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. J. Virol. 78, 9007-9015 (2004).","title":"Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein","venue":"J. Virol","year":2004},{"authors":["C Shema Mugisha"],"raw":"Shema Mugisha, C. et al. A simplified quantitative real-time PCR assay for monitoring SARS-CoV-2 growth in cell culture. mSphere. 5, e00658-20 (2020).","title":"A simplified quantitative real-time PCR assay for monitoring SARS-CoV-2 growth in cell culture","year":2020},{"kind":"footnote","raw":"NATURE COMMUNICATIONS | (2021) 12:3802 | https://doi.org/10.1038/s41467-021-24013-y | www.nature.com/naturecommunications","url":"https://doi.org/10.1038/s41467-021-24013-y"}]}